Combining naproxen and a dual amylin and calcitonin receptor agonist improves pain and structural outcomes in the collagen-induced arthritis rat model
Abstract Background Pain is a debilitating symptom of rheumatoid arthritis (RA), caused by joint inflammation and cartilage and bone destruction. Nonsteroidal anti-inflammatory drugs (NSAIDs) are used to treat pain and inflammation in RA, but are not disease-modifying and do not prevent joint destru...
Main Authors: | Anna Katri, Aneta Dąbrowska, Henrik Löfvall, Ming Ding, Morten A. Karsdal, Kim V. Andreassen, Christian S. Thudium, Kim Henriksen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-02-01
|
Series: | Arthritis Research & Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13075-019-1819-9 |
Similar Items
-
Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases
by: Nina Sonne, et al.
Published: (2021-04-01) -
The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile
by: Anna Thorsø Larsen, et al.
Published: (2021-01-01) -
KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats
by: K.V. Andreassen, et al.
Published: (2021-11-01) -
Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat
by: David S. Mathiesen, et al.
Published: (2021-01-01) -
Metabolomic Biomarker Candidates for Skeletal Muscle Loss in the Collagen-Induced Arthritis (CIA) Model
by: Paulo V. G. Alabarse, et al.
Published: (2021-08-01)